================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: March 16, 2004
QLT Inc.
------------------------------------------------------
(Exact name of registrant as specified in its Charter)
British Columbia, Canada 000-17082 N/A
- ------------------------ ------------------------ -------------------
(Jurisdiction of (Commission File Number) (IRS Employer
Incorporation) Identification No.)
QLT Inc.,
887 Great Northern Way,
Vancouver, B.C., CANADA, V5T 4T5
(604) 707-7000
----------------------------------------------------
(Address, including zip code, and telephone number,
including area code, of principal executive offices)
================================================================================
ITEM 5. OTHER EVENTS
On March 16, 2004, QLT Inc. announced that the Centers for Medicare
and Medicaid Services has raised the Medicare allowable reimbursement
rate for Visudyne(R). Effective April 1, 2004, the rate moves from
approximately $1,304 to $1,404, as part of the Medicare Prescription
Drug, Improvement, and Modernization Act of 2003.
ITEM 7. EXHIBITS
Exhibit
Number Description
- ------ -----------
99.1 Press release dated March 16, 2004
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
QLT Inc.
------------------------------------------
(Registrant)
Date March 16, 2004 /s/ Paul J. Hastings
------------------ -------------------------------------
(Signature)
President and Chief Executive Officer